Caribou Biosciences Starts Phase 1 Trial for Lupus Drug Candidate

MT Newswires04:47 ET

Express News | Reported Earlier, Caribou Biosciences Advances CB-010, CB-011, And CB-012 Programs With Key Clinical Updates Expected In 2025; Cash Position $281M

Benzinga02:33 ET

Caribou Biosciences Initiates Phase 1 Clinical Trials for CB-010 in Lupus and Advances Multiple CAR-T Therapy Programs

Quiver Quantitative19:10 ET

Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025

GlobeNewswire19:05 ET

Express News | Caribou Biosciences Initiates the CB-010 Gallop Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025

Reuters19:05 ET

BofA Securities Cuts Price Target on Caribou Biosciences to $11 From $13, Maintains Buy Rating

MT NewswiresJan 7 10:40 ET · Ratings